WAT - Educational Analysis * US Equities
Educational Analysis * US Equities

WAT

Earnings behavior, post-earnings drift, and the gap between consensus and the market's real expectation - the educational primer before you look at the institutional verdict.

Educational content only - not investment advice. Nothing on this page is a recommendation to buy or sell any security. Historical patterns do not predict future outcomes. Consult a licensed financial advisor before making any trading decision.
Published byGamma QC editorial
TickerWAT
CategoryEducational primer
Last reviewedNovember 17, 2026
You're viewing an older edition of this page.Read the latest edition →

Business profile & competitive position

Waters Corporation operates in the Healthcare sector, specifically in the Medical – Diagnostics & Research industry. Its core business is designing, manufacturing, selling, and servicing analytical instruments: high-performance and ultra-performance liquid chromatography (LC), mass spectrometry (MS), thermal analysis, rheometry, and calorimetry (TA) systems. These products are typically sold as integrated LC-MS platforms with shared software, consumables, and service contracts to pharmaceutical, clinical, biochemical, industrial, environmental, nutritional safety, academic, and government laboratories.

Following the February 9, 2026 acquisition of BD’s Biosciences and Diagnostic Solutions businesses, Waters also participates in diagnostics specimen collection, infectious-disease and cancer testing systems, flow cytometry, and multiomics tools. In 2025, 59% of net sales came from pharmaceutical accounts, 30% from industrial customers, and 11% from academic and government agencies, with no single customer exceeding 2% of net sales. Service revenue represented more than 35% of Waters’ 2025 sales and more than 25% of TA’s 2025 sales, pointing to a recurring-revenue component built around an installed base of instruments.

That installed base and recurring service mix normally support durable competitive positioning, but the real margin figures tell a more complicated story right now. Net margin is just 1.8% and return on equity is 0.8%. Those are unusually low for a company that historically has been associated with premium analytical instrumentation. One plausible reading is that the $16.8 billion BDS acquisition—closed as a Reverse Morris Trust—has temporarily depressed reported margins through goodwill, financing costs, integration expense, and segment reorganization. Another reading is that product mix has shifted toward lower-margin diagnostics hardware. Either way, the 1.8% net margin and 0.8% ROE imply that competitive moat is currently being masked by acquisition-related financial noise rather than by weak pricing power alone.

Financial posture

Waters currently carries a market capitalization of $44.6 billion and trades at a P/E ratio of 192.9, both measured against a net margin of 1.8% and an ROE of 0.8%. A P/E near 193 is extremely high on trailing earnings, especially for a business with sub-2% profitability and sub-1% returns on equity. That disconnect is consistent with the market treating Waters as a post-transformation story: investors appear willing to pay a steep multiple because they expect margins and returns to recover as the BD diagnostic assets are integrated and as R&D investments convert into new product cycles.

Beta is 1.15, meaning the stock has historically moved about 15% more than the broad market on average. The current price is $453.42, with a 50-day exponential moving average of $443.32 and an RSI of 49.1. The RSI near the middle of the range suggests neither strong overbought nor oversold conditions from a short-term technical perspective. Importantly, the company’s reported valuation is not being supported by current earnings power; it is being supported by expectations of future execution. That leaves the stock sensitive to any changes in integration timeline, synergy realization, or analyst consensus around the 2027-02-08 earnings report.

Strategic priorities & outlook

Waters’ most recent 10-K frames the near-term focus around digesting the BDS acquisition and reorganizing the combined company. Management plans to operate four segments: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials Sciences. The filing notes that the company is still evaluating the newly organized activities to determine how operating and reporting segments will be presented in future periods.

R&D remains a central priority. The company intends to continue significant investment to develop new products and enhance existing LC, MS, TA, and diagnostics offerings. It also plans to pursue additional outsourcing opportunities where appropriate while maintaining adequate internal supply chain and manufacturing capabilities. The acquisition closed on February 9, 2026 for a total purchase price of $16.8 billion including assumed debt, structured as a Reverse Morris Trust transaction. BD shareholders ended up owning approximately 39.2% of the combined company, giving Waters a much larger diagnostics footprint and a very different revenue mix than before the deal.

Macro & geopolitical exposure

As a Healthcare / Medical – Diagnostics & Research company, Waters is exposed to several macro and geopolitical factors that typically matter for the industry. Regulatory risk is foremost: clinical flow cytometry and diagnostics tests require FDA clearance or 510(k) clearance, and any changes in U.S. or overseas diagnostic regulation can affect product launch schedules and reimbursement. Reimbursement trends for clinical testing also influence demand for diagnostic platforms, particularly in cancer and infectious-disease testing.

Pharmaceutical R&D spending is cyclical and sensitive to interest rates, biotech funding availability, and capital markets. Because 59% of 2025 sales were pharmaceutical accounts, softness in biotech funding or Big Pharma capital budgets can directly pressure instrument demand. Trade policy and tariffs matter too: analytical instruments and consumables often move across borders multiple times during manufacturing and final sale, so changes in U.S.-China or trans-Atlantic trade frictions can affect both costs and pricing. Supply-chain resilience and currency swings are additional variables, since Waters’ customer base is global and instrument contracts are frequently denominated in local currencies. Finally, large-scale M&D transactions can attract antitrust or national-security review, especially where healthcare diagnostics are involved.

Recent developments

Recent news has centered on two themes: regulatory approvals in diagnostics and expansion in proteomics. On November 11, 2026, Zacks reported that Waters gained FDA clearance for flow cytometry tests for blood cancers. One day earlier, on November 10, 2026, PR Newswire announced that the company achieved FDA 510(k) clearance for ready-to-use flow cytometry clinical tests for leukemia and lymphoma. These approvals fit the BDS acquisition thesis by turning Waters’ new flow-cytometry capabilities into commercial, regulated clinical products.

On November 9, 2026, Zacks reported that Waters expanded its proteomics reach through the acquisition of MOBILion Systems. That move aligns with the 10-K emphasis on continuous R&D and new product development in LC-MS applications. On the portfolio-manager side, a November 6, 2026 Seeking Alpha headline noted Madison Mid Cap Fund’s third-quarter 2026 portfolio activity involving Waters. While that item does not carry fundamental news, it reflects ongoing institutional position reassessment after the company’s strategic transformation.

Earnings behavior & post-earnings drift

Waters has a perfect beat rate over the last eight reported quarters: 8 for 8, with an average earnings surprise of 3.8%. The average 5-day price move in the trading days following those reports is +2.22%, which is classified as an “up” post-earnings drift. That pattern suggests the stock has generally continued to climb after quarterly beats rather than selling off on good news.

The most recent quarters show the trend is not uniform. For the November 3, 2026 report, Waters posted EPS of $4.10 versus the $4.00 estimate, a 2.5% surprise. The stock rose 1.67% the next session and 3.4% over the following five days. On August 4, 2026, EPS came in at $3.05 against a $3.01 estimate, a 1.3% surprise, with the stock up 0.99% the next day and 4.78% over the next five sessions. The May 5, 2026 report was the strongest beat in this window: $2.70 versus $2.31, a 16.9% surprise, driving a 1.98% next-day move and a 2.76% five-day drift. The February 9, 2026 quarter was the exception: EPS of $4.53 versus $4.51, only a 0.4% surprise, led to a 0.34% decline the next day and a 2.04% decline over the subsequent five sessions.

Waters is scheduled to report next on February 8, 2027 before the market open, with a consensus EPS estimate of $4.63. Traders often compare reported results against the official consensus and the market’s real expectation. Because the company has beaten in every one of the last eight quarters, the historical beat rate is 100%, but the size of the surprise and any guidance around integration costs will likely matter more than the binary beat itself.

Frequently Asked Questions

What does Waters Corporation primarily sell?

Waters primarily sells analytical instruments—liquid chromatography, mass spectrometry, thermal analysis, rheometry, and calorimetry systems—along with consumables, software, and service plans. After acquiring BD’s Biosciences and Diagnostic Solutions businesses on February 9, 2026, it also sells diagnostics specimen collection, infectious-disease and cancer testing systems, flow cytometry, and multiomics tools.

Why are Waters’ net margin and ROE so low?

Waters reports a 1.8% net margin and a 0.8% ROE, well below what investors normally associate with premium analytical-instrument companies. The low figures likely reflect the financial and operational impact of the $16.8 billion BDS acquisition, including integration costs, segment reorganization, and a larger diagnostics hardware mix, rather than a permanent erosion of pricing power.

How has WAT behaved after earnings historically?

Over the last eight reported quarters, Waters has beaten estimates every time, with an average earnings surprise of 3.8%. The average 5-day post-earnings price move is +2.22%, indicating a positive post-earnings drift, although individual quarters vary—the February 9, 2026 report saw a five-day decline of 2.04% despite a small beat.

For a deeper dive into how institutional analysts are weighing the BDS integration, upcoming segment reporting, and the February 2027 earnings setup, review the full institutional verdict on Waters Corporation.

Real Data - Gamma QC Earnings IntelligenceAs of Nov 17, 2026
Waters Corporation · Healthcare / Medical - Diagnostics & Research
$44.6BMarket cap
192.9P/E
1.8%Net margin
0.8%ROE
100%Beat rate, last 8Q
3.8%Avg EPS surprise
2.22%Avg 5-day move after earnings
2027-02-08Next earnings
ReportedActualEstimateSurprise1D Move5D Move
2026-11-03$4.1$4+2.5%+1.67%+3.4%
2026-08-04$3.05$3.01+1.3%+0.99%+4.78%
2026-05-05$2.7$2.31+16.9%+1.98%+2.76%
2026-02-09$4.53$4.51+0.4%-0.34%-2.04%
2025-11-04$3.4$3.21+5.9%--
2025-08-04$2.95$2.94+0.3%--

Previous WAT editions

Beyond the primer

Get the institutional verdict on WAT

Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.

Read the WAT verdict at Gamma QC
$49 Pro / $249 RIA * gammaqc.com

Verify authenticity

Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.